Infergen, Ribavirin & Avandia in Previous Relapsers or Nonresponders to Pegylated Interferon and Ribavirin

Inclusion Criteria: * Participants willing to give written informed consent and able to adhere to dose and visit schedules. * Adult participants 18 years of age or older of either gender or any race. Participants who are over 65 years of age must be in generally good health. * HCV-antibody (Ab) or HCV-RNA positive by polymerase chain reaction (PCR) for at least 6 months. * Serum positive for HCV-RNA by PCR assay. * Subjects must be previous nonresponders or relapsers on pegylated interferon and ribavirin therapy. * Liver biopsy within 24 months prior to enrollment into the protocol. * Compensated liver disease with the following minimum hematological, biochemical, and serologic criteria at the Screening Visit (WNL = within normal limits): * Hemoglobin values of \< 12 gm/dL for females and \< 13 gm/dL for males. * White blood cells (WBC) \< 3,000/mm3 * Neutrophil count \< 1,500/mm3 * Platelets \< 65,000/mm3 * Direct bilirubin, within 20% of upper limits of normal (ULN) * Indirect bilirubin, (WNL) (unless non-hepatitis related factors such as Gilbert's disease explain an indirect bilirubin rise. In such cases indirect bilirubin must be \< 3.0 mg/dL \[\< 51.3 µmol/L\]). * Albumin \> 3 gm/dL * Serum creatinine \< 20% of ULN * Thyroid stimulating hormone (TSH) WNL * Alpha fetoprotein value \< 100 ng/mL. * Reconfirmation and documentation that sexually active female subjects of childbearing potential are practicing adequate contraception during the treatment period and for 6 months following the last dose of study medication. Female subjects must not be breast-feeding. * Reconfirmation that sexually active male subjects are practicing two acceptable methods of contraception during the treatment period and for 6 months following the last dose of study medication. Exclusion Criteria: * Inability or unwillingness to provide informed consent or abide by the requirements of the study * Participants on insulin are excluded. * Participants on metformin or another thiazolidinedione must have a three-month wash-out period to be considered for the study. * Women who are pregnant or breast-feeding * Males whose female partner is pregnant * No other thiazolidinedione after liver biopsy and/or during the entire study (other than those subjects randomized to receive rosiglitazone during the study) * Hepatitis C of non-genotype 1 * Suspected hypersensitivity to interferon, ribavirin, or rosiglitazone * Any cause for liver disease other than chronic hepatitis C, insulin resistance, or non-alcoholic fatty liver disease (NAFLD), including but not limited to: * Hemochromatosis * Alpha-1 antitrypsin deficiency * Co-infection with hepatitis B virus (HBV) \[serum hepatitis B surface antigen (HBsAg) positive\] * Wilson's disease * Autoimmune hepatitis * Alcoholic liver disease (consumption of greater than 2 drinks a day on average) * Drug-related liver disease * Any condition that would prevent the subject from having a liver biopsy. * Hemoglobinopathies that could potentially compromise patient safety (e.g., beta thalassemia major, sickle cell disease) * Evidence of advanced liver disease * Participants with organ transplants other than cornea and hair transplant * Any known preexisting medical condition that could interfere with the subject's participation in and completion of the protocol such as: * Preexisting psychiatric condition, especially severe depression, or a history of severe psychiatric disorder, such as major psychoses, suicidal ideation and/or suicidal attempt. * Participants with a history of mild depression may be considered for entry into the protocol provided that a pretreatment assessment of the subject's mental status supports that the participant is clinically stable.